Advertisement

Adolescent social isolation affects parvalbumin expression in the medial prefrontal cortex in the MAM-E17 model of schizophrenia

  • Marzena Maćkowiak
  • Joachim Latusz
  • Urszula Głowacka
  • Ewelina Bator
  • Wiktor Bilecki
Original Article

Abstract

Altered parvalbumin (PV) expression is observed in the prefrontal cortex of subjects with schizophrenia. Environmental context, particularly during adolescence, might regulate PV expression. In the present study, we investigated the effect of adolescent social isolation (SI) on PV expression in the medial prefrontal cortex in a neurodevelopmental model (MAM-E17) of schizophrenia. SI exposure occurred from postnatal day 30 to 40, followed by resocialization until late adolescence or early adulthood. PV mRNA and protein levels, as well as the number of PV cells, were analysed at these ages. Moreover, epigenetic regulation of PV expression by histone methylation was examined by measuring the total and PV gene-bound H3K4me3 levels. MAM only decreased levels of the PV mRNA and protein in adulthood. Decreases in total H3K4me3 levels and its level at the PV gene were also observed at this age. In contrast, in late adolescence, SI induced a decrease in the expression of the PV mRNA in the MAM group that was related to the reduction in total and PV gene-bound H3K4me3 levels. However, at this age, SI increased the levels of the PV protein in both the control and MAM groups. In adulthood, SI did not affect PV mRNA or H3K4me3 levels but decreased levels of the PV protein in both groups. Both MAM and SI failed to change the number of PV cells at any age. The results indicate that adolescent SI accelerated epigenetic impairments of PV expression in MAM-E17 rats; however, subsequent resocialization abolished this dysfunction, but failed to prevent alterations in PV protein.

Keywords

Environment Risk factor Schizophrenia Epigenetics Neurodevelopment 

Notes

Acknowledgements

The study was supported by grant 2014/13/B/NZ4/00218 funded by the National Science Centre, Poland and statutory activity of Institute of Pharmacology, Polish Academy of Sciences.

Funding

The study was supported by grant 2014/13/B/NZ4/00218 from the National Science Center, Poland and statutory activity of Institute of Pharmacology, Polish Academy of Sciences.

Compliance with ethical standards

Ethical approval

All applicable international, national and institutional guidelines for the care and use of animals were followed. All procedures performed in the studies involving animals were conducted in accordance with the ethical standards of the institution or practice at which the studies were conducted. The study was performed in strict accordance with the recommendations of the European Council Guide for the Care and Use of Laboratory Animals (86/609/EEC), as adopted and promulgated by the European Communities Council Directive (2010/63/EU). The protocols were approved by the Committee for Laboratory Animal Welfare and the Ethics of the Institute of Pharmacology, Polish Academy of Sciences in Kraków. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. Bator E, Latusz J, Wedzony K, Mackowiak M (2018a) Adolescent environmental enrichment prevents the emergence of schizophrenia-like abnormalities in a neurodevelopmental model of schizophrenia. Eur Neuropsychopharmacol 28:97–108CrossRefPubMedGoogle Scholar
  2. Bator E, Latusz J, Glowacka U, Radaszkiewicz A, Mudlaff K, Mackowiak M (2018b) Adolescent social isolation affects schizophrenia-like behavior in the MAM-E17 model of schizophrenia. Neurotox Res 34:305–323CrossRefPubMedGoogle Scholar
  3. Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349–355CrossRefPubMedGoogle Scholar
  4. Beasley CL, Zhang ZJ, Patten I, Reynolds GP (2002) Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 52:708–715CrossRefPubMedGoogle Scholar
  5. Burke AR, McCormick CM, Pellis SM, Lukkes JL (2017) Impact of adolescent social experiences on behavior and neural circuits implicated in mental illnesses. Neurosci Biobehav Rev 76:280–300CrossRefPubMedGoogle Scholar
  6. Buwalda B, Geerdink M, Vidal J, Koolhaas JM (2011) Social behavior and social stress in adolescence: a focus on animal models. Neurosci Biobehav Rev 35:1713–1721CrossRefPubMedGoogle Scholar
  7. Caballero A, Tseng KY (2016) GABAergic function as a limiting factor for prefrontal maturation during adolescence. Trends Neurosci 39:441–448CrossRefPubMedPubMedCentralGoogle Scholar
  8. Caballero A, Flores-Barrera E, Cass DK, Tseng KY (2014) Differential regulation of parvalbumin and calretinin interneurons in the prefrontal cortex during adolescence. Brain Struct Funct 219:395–406CrossRefPubMedGoogle Scholar
  9. Caballero A, Granberg R, Tseng KY (2016) Mechanisms contributing to prefrontal cortex maturation during adolescence. Neurosci Biobehav Rev 70:4–12CrossRefPubMedPubMedCentralGoogle Scholar
  10. Chen L, Perez SM, Lodge DJ (2014) An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia. Dev Neurobiol 74:907–917CrossRefPubMedPubMedCentralGoogle Scholar
  11. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, Everall I (2002) The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 51:377–386CrossRefPubMedGoogle Scholar
  12. DeFelipe J, Lopez-Cruz PL, Benavides-Piccione R, Bielza C, Larranaga P, Anderson S, Burkhalter A, Cauli B, Fairen A, Feldmeyer D, Fishell G, Fitzpatrick D, Freund TF, Gonzalez-Burgos G, Hestrin S, Hill S, Hof PR, Huang J, Jones EG, Kawaguchi Y, Kisvarday Z, Kubota Y, Lewis DA, Marin O, Markram H, McBain CJ, Meyer HS, Monyer H, Nelson SB, Rockland K, Rossier J, Rubenstein JL, Rudy B, Scanziani M, Shepherd GM, Sherwood CC, Staiger JF, Tamas G, Thomson A, Wang Y, Yuste R, Ascoli GA (2013) New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat Rev Neurosci 14:202–216CrossRefPubMedPubMedCentralGoogle Scholar
  13. Du Y, Grace AA (2016) Loss of Parvalbumin in the Hippocampus of MAM schizophrenia model rats is attenuated by Peripubertal diazepam. Int J Neuropsychopharmacol 19:pyw065CrossRefPubMedPubMedCentralGoogle Scholar
  14. Fachim HA, Srisawat U, Dalton CF, Harte MK, Marsh S, Neill JC, Reynolds GP (2016) Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain. Epigenomics 8:1179–1183CrossRefPubMedGoogle Scholar
  15. Fachim HA, Srisawat U, Dalton CF, Reynolds GP (2018) Parvalbumin promoter hypermethylation in postmortem brain in schizophrenia. Epigenomics 10:519–524CrossRefPubMedGoogle Scholar
  16. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS (2010) Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 167:1479–1488CrossRefPubMedGoogle Scholar
  17. Gaskin PL, Toledo-Rodriguez M, Alexander SP, Fone KC (2016) Down-regulation of hippocampal genes regulating dopaminergic, GABAergic, and glutamatergic function following combined neonatal phencyclidine and post-weaning social isolation of rats as a neurodevelopmental model for schizophrenia. Int J Neuropsychopharmacol 19:pyw062CrossRefPubMedPubMedCentralGoogle Scholar
  18. Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins TW, Tricklebank MD (2012) Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 37:1057–1066CrossRefPubMedGoogle Scholar
  19. Gilabert-Juan J, Belles M, Saez AR, Carceller H, Zamarbide-Fores S, Molto MD, Nacher J (2013) A "double hit" murine model for schizophrenia shows alterations in the structure and neurochemistry of the medial prefrontal cortex and the hippocampus. Neurobiol Dis 59:126–140CrossRefPubMedGoogle Scholar
  20. Gill KM, Grace AA (2014) Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model. Int J Neuropsychopharmacol 17:1609–1619CrossRefPubMedPubMedCentralGoogle Scholar
  21. Glausier JR, Fish KN, Lewis DA (2014) Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects. Mol Psychiatry 19:30–36CrossRefPubMedGoogle Scholar
  22. Gonzalez-Burgos G, Cho RY, Lewis DA (2015) Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry 77:1031–1040CrossRefPubMedPubMedCentralGoogle Scholar
  23. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315–6326CrossRefPubMedGoogle Scholar
  24. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA (2008) Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 165:479–489CrossRefPubMedPubMedCentralGoogle Scholar
  25. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, Wang W, Weng Z, Green RD, Crawford GE, Ren B (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39: 311–318Google Scholar
  26. Hieronymus H, Silver PA (2003) Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery. Nat Genet 33:155–161CrossRefPubMedGoogle Scholar
  27. Hoftman GD, Volk DW, Bazmi HH, Li S, Sampson AR, Lewis DA (2015) Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. Schizophr Bull 41:180–191CrossRefPubMedGoogle Scholar
  28. Hu H, Gan J, Jonas P (2014) Interneurons. Fast-spiking, parvalbumin(+) GABAergic interneurons: from cellular design to microcircuit function. Science 345:1255263CrossRefPubMedGoogle Scholar
  29. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S (2007) Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci 27:11254–11262CrossRefPubMedGoogle Scholar
  30. Jiang Z, Cowell RM, Nakazawa K (2013) Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia. Front Behav Neurosci 7:116PubMedPubMedCentralGoogle Scholar
  31. Kaalund SS, Riise J, Broberg BV, Fabricius K, Karlsen AS, Secher T, Plath N, Pakkenberg B (2013) Differential expression of parvalbumin in neonatal phencyclidine-treated rats and socially isolated rats. J Neurochem 124:548–557CrossRefPubMedGoogle Scholar
  32. Kaufman DL, Houser CR, Tobin AJ (1991) Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem 56:720–723CrossRefGoogle Scholar
  33. Kisby GE, Moore H, Spencer PS (2013) Animal models of brain maldevelopment induced by cycad plant genotoxins. Birth Defects Res C Embryo Today 99:247–255CrossRefPubMedPubMedCentralGoogle Scholar
  34. Koh DX, Sng JC (2016) HDAC1 negatively regulates Bdnf and Pvalb required for parvalbumin interneuron maturation in an experience-dependent manner. J Neurochem 139:369–380CrossRefPubMedPubMedCentralGoogle Scholar
  35. Lewis DA (2012) Cortical circuit dysfunction and cognitive deficits in schizophrenia--implications for preemptive interventions. Eur J Neurosci 35:1871–1878CrossRefPubMedPubMedCentralGoogle Scholar
  36. Lodge DJ, Behrens MM, Grace AA (2009) A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci 29:2344–2354CrossRefPubMedPubMedCentralGoogle Scholar
  37. Mackowiak M, Bator E, Latusz J, Mordalska P, Wedzony K (2014) Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur Neuropsychopharmacol 24:271–289CrossRefPubMedPubMedCentralGoogle Scholar
  38. Millan MJ (2013) An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 68:2–82CrossRefPubMedPubMedCentralGoogle Scholar
  39. Modinos G, Allen P, Grace AA, McGuire P (2015) Translating the MAM model of psychosis to humans. Trends Neurosci 38:129–138CrossRefPubMedPubMedCentralGoogle Scholar
  40. Morishita H, Kundakovic M, Bicks L, Mitchell A, Akbarian S (2015) Interneuron epigenomes during the critical period of cortical plasticity: implications for schizophrenia. Neurobiol Learn Mem 124:104–110CrossRefPubMedPubMedCentralGoogle Scholar
  41. Nott A, Cho S, Seo J, Tsai LH (2015) HDAC2 expression in parvalbumin interneurons regulates synaptic plasticity in the mouse visual cortex. Neuroepigenetics 1:34–40CrossRefPubMedPubMedCentralGoogle Scholar
  42. Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT (2006) Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci 23:279–284CrossRefPubMedGoogle Scholar
  43. Powell SB, Sejnowski TJ, Behrens MM (2012) Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology 62:1322–1331CrossRefPubMedGoogle Scholar
  44. Sakai T, Oshima A, Nozaki Y, Ida I, Haga C, Akiyama H, Nakazato Y, Mikuni M (2008) Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology 28:143–150CrossRefPubMedGoogle Scholar
  45. Schiavone S, Sorce S, Dubois-Dauphin M, Jaquet V, Colaianna M, Zotti M, Cuomo V, Trabace L, Krause KH (2009) Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry 66:384–392CrossRefPubMedGoogle Scholar
  46. Schmitt A, Malchow B, Hasan A, Falkai P (2014) The impact of environmental factors in severe psychiatric disorders. Front Neurosci 8:19CrossRefPubMedPubMedCentralGoogle Scholar
  47. Selemon LD, Zecevic N (2015) Schizophrenia: a tale of two critical periods for prefrontal cortical development. Transl Psychiatry 5:e623CrossRefPubMedPubMedCentralGoogle Scholar
  48. Solnestam BW, Stranneheim H, Hallman J, Kaller M, Lundberg E, Lundeberg J, Akan P (2012) Comparison of total and cytoplasmic mRNA reveals global regulation by nuclear retention and miRNAs. BMC Genomics 13:574CrossRefPubMedPubMedCentralGoogle Scholar
  49. Tooney PA, Chahl LA (2004) Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 28:273–278CrossRefGoogle Scholar
  50. Ueno H, Suemitsu S, Murakami S, Kitamura N, Wani K, Okamoto M, Matsumoto Y, Ishihara T (2017) Region-specific impairments in parvalbumin interneurons in social isolation-reared mice. Neuroscience 359:196–208CrossRefPubMedGoogle Scholar
  51. van Os J, Rutten BP, Poulton R (2008) Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 34:1066–1082CrossRefPubMedPubMedCentralGoogle Scholar
  52. Volk DW, Lewis DA (2013) Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. Neuroscience 248:154–164CrossRefPubMedGoogle Scholar
  53. Woo TU, Miller JL, Lewis DA (1997) Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 154:1013–1015CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Marzena Maćkowiak
    • 1
  • Joachim Latusz
    • 1
  • Urszula Głowacka
    • 1
  • Ewelina Bator
    • 1
  • Wiktor Bilecki
    • 1
  1. 1.Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, Laboratory of Pharmacology and Brain BiostructureKrakówPoland

Personalised recommendations